Abstract
The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 129-132 |
Number of pages | 4 |
Journal | Investigational New Drugs |
Volume | 12 |
Issue number | 2 |
DOIs | |
State | Published - Jun 1994 |
Keywords
- breast cancer
- cis-platinum
- mitoxantrone
- phase I-II trial
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)